Rapid Micro Biosystems Q2 2026 revenue rose 11% to USD 8.1 million, driven by product revenue of USD 5.3 million.
Net loss widened to USD 12.9 million; loss per share was USD 0.27.
Gross margin climbed to 15%, up 11 percentage points from a year earlier.
The company placed four Growth Direct systems, completed nine validations, and reached the 200th system placed globally.
Rapid Micro Biosystems reaffirmed 2026 revenue guidance of USD 37 million-USD 41 million and expects 30-38 system placements, with gross margin about 20%.
RPID•
